Magic mushroom compound holds promise for depression
Friday, 06 November, 2020
The active compound in magic mushrooms 鈥 psilocybin 鈥 has been found to produce large, rapid and sustained improvements in patients with treatment-resistant major depressive disorder (MDD), according to a small study conducted at the at Johns Hopkins Bayview Medical Center.
The 27 patients eligible to participate in the trial underwent two sessions of psilocybin therapy combined with supportive psychotherapy. Participants were split into two groups, one of which received treatment immediately, while the other received treatment after an eight-week delay. This allowed the researchers to compare similar groups of patients, and see if the immediate treatment group improved compared with the delayed treatment group.
The results of the study are published in .
After the psilocybin session, 67% (16) of participants at week one and 71% (17) of participants at week four had a clinically significant response to the intervention, with 鈮50% reduction in GRID-HAMD score (0鈥7: no depression; 8鈥16: mild depression; 17鈥23: moderate depression; 鈮24: severe depression).
At week one and four, 58% (14) and 54% (13) of participants, respectively, met the criteria for remission of depression (鈮7 GRID-HAMD score).
Overall, more than two in three patients showed improvements four weeks after their sessions ended, and more than half were in remission at the four-week point.
The study authors commented that although the rapid antidepressant effects of psilocybin are similar to those reported with ketamine 鈥 also being studied for the treatment of severe and treatment-resistant depression 鈥 the response to psilocybin therapy persisted for at least four weeks (ketamine effects typically last for a few days to two weeks).
The authors explained that the results obtained in this trial were 2.5 times greater than the effect sizes found with psychotherapy studies and four times greater than those in studies of psychopharmacological treatment for depression.
鈥淔urther studies are needed with active treatment or placebo controls and in larger and more diverse populations,鈥 the authors said.
$12m for homegrown heart disease and diabetes innovations
$12 million in federal funding has been announced for the development of new Australian-made...
National cancer screening program marks first in almost 20 years
From 1 July, the National Lung Cancer Screening Program will commence — marking the first...
Doctor deregistered after botched facelift calls for ambulance
A Queensland doctor has been deregistered after a botched cosmetic surgery procedure left a...